Norbert Pardi - Selected Publications#

As of now (January 13, 2024), Norbert Pardi's H index is 40, his work received more than 11,000 citations, over 3,000 citations/year just in the past 2 years. He published more than 80 review and research papers in the field of mRNA medicines in the past 8 years.

In all listed papers below Norbert Pardi is the last/co-last and corresponding author. All listed papers have an impact factor of >10. All listed papers are/will be highly cited publications.

1. Development of an mRNA-lipid nanoparticle vaccine against Lyme disease
Pine M, Arora G, Hart TM, Bettini E, Gaudette BT, Muramatsu H, Tombácz I, Kambayashi T, Tam YK, Brisson D, Allman D, Locci M, Weissman D, Fikrig E, Pardi N.
Mol Ther. 2023 Sep 6; 31(9): 2702-2714. doi: 10.1016/j.ymthe.2023.07.022.

2. Single dose treatment with self-amplifying or non-replicating mRNA-LNP vaccines controls HPV-associated tumors in mice
Ramos da Silva J, Bitencourt Rodrigues K, Formoso Pelegrin G, Silva Sales N, Muramatsu H, de Oliveira Silva M, F.M.M. Porchia M, Ramos Moreno AC, M.M. Aps LR, Venceslau-Carvalho AA, Tombácz I, Luzetti Fotoran W, Karikó K, Lin PJC, Tam YK, de Oliveira Diniz M, Pardi N, de Souza Ferreira LC.
Science Translational Medicine, 2023 Mar 8;15(686):eabn3464. doi: 10.1126/scitranslmed.abn3464.

3. A universal influenza mRNA vaccine candidate boosts T-cell responses and reduces zoonotic influenza virus disease in ferrets
van de Ven K, Lanfermeijer J, van Dijken H, Muramatsu H, Boas de Melo CV, Lenz S, Peters F, Beattie MB, Lin PJC, Ferreira JA, van den Brand J, van Baarle D, Pardi N, de Jonge J.
Science Advances, 2022 Dec 14;8(50):eadc9937.

4. Innate immune mechanisms of mRNA vaccines
Verbeke R, Lore K, Hogan MJ, Pardi N.
Immunity 2022 Nov 8; 55(11): 1993-2005.

5. Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses
McMahon M, O'Dell G, Tan J, Sárközy A, Vadovics M, Carreño JM, Puente-Massaguer E, Muramatsu H, Bajusz C, Rijnink W, Beattie M, Tam YK, Kirkpatrick Roubidoux E, Francisco I, Strohmeier S, Kanekiyo M, Graham BS, Krammer F, Pardi N.
Proc Natl Acad Sci U S A. 2022 Nov 8;119(45):e2206333119

6. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses
Pardi N, Carreño JM, O'Dell G, Tan J, Bajusz C, Muramatsu H, Rijnink W, Strohmeier S, Loganathan M, Bielak D, Sung MMH, Tam YK, Krammer F, McMahon M.
Nat Commun. 2022 Aug 9; 13(1):4677

7. Muramatsu H, Lam K, Bajusz C, Laczkó D, Karikó K, Schreiner P, Martin A, Lutwyche P, Heyes J, Pardi N.
Lyophilization provides long-term stability for a lipid nanoparticle-formulated nucleoside-modified mRNA vaccine
Mol Ther. 2022 May 4;30(5):1941-1951

8. Hogan MJ, Pardi N.
mRNA Vaccines in the COVID-19 Pandemic and Beyond
Annu Rev Med. 2022 Jan 27; 73: 17-39

9. Alameh MG, Tombácz I, Bettini E, Lederer K, Sittplangkoon C, Wilmore JR, Gaudette BT, Soliman O, Pine M, Hicks P, Manzoni TB, Knox JJ, Johnson JL, Laczkó D, Muramatsu H, Davis B, Meng W, Rosenfeld AM, Strohmeier S, Lin PJC, Mui BL, Tam YK, Karikó K, Jacquet A, Krammer F, Bates P, Cancro MP, Weissman D, Prak ET, Allman D, Locci M, Pardi N.
A lipid nanoparticle formulation is a broadly applicable adjuvant for induction of potent T follicular helper cell and humoral immune responses
Immunity. 2021 Dec. 14; 54: 2877-2892

10. Laczkó D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, Castaño D, Amanat F, Muramatsu H, Oguin TH 3rd, Ojha A, Zhang L, Mu Z, Parks R, Manzoni TB, Roper B, Strohmeier S, Tombácz I, Arwood L, Nachbagauer R, Karikó K, Greenhouse J, Pessaint L, Porto M, Putman-Taylor T, Strasbaugh A, Campbell TA, Lin PJC, Tam YK, Sempowski GD, Farzan M, Choe H, Saunders KO, Haynes BF, Andersen H, Eisenlohr LC, Weissman D, Krammer F, Bates P, Allman D, Locci M, Pardi N
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice
Immunity 2020 Oct 13; 53(4):724-732.e7